Form 4 Filing for James C. Momtazee

This filing details transactions made by James C. Momtazee, a director at BridgeBio Pharma, Inc. On June 22, 2026, Momtazee acquired 3,990 shares of Common Stock and a stock option to purchase 5,277 shares. The acquisition of Common Stock was part of a grant of restricted stock units (RSUs) under the company's incentive plan, which vest on June 22, 2027. The stock option also vests on June 22, 2027, contingent upon continued service. Additionally, 80,000 shares previously held directly are now reported as indirectly owned through the James C. Momtazee Revocable Trust. The filing also includes a power of attorney document authorizing specific individuals to execute SEC filings on Momtazee's behalf.